F. Selcukbiricik Et Al. , "Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer," Journal of Clinical Pharmacy and Therapeutics , vol.45, no.2, pp.303-308, 2020
Selcukbiricik, F. Et Al. 2020. Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer. Journal of Clinical Pharmacy and Therapeutics , vol.45, no.2 , 303-308.
Selcukbiricik, F., Ozdogan, E., Dagel, T., Tanju, S., Erus, S., Ertuglu, L. A., ... Kapdağlı, M.(2020). Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer. Journal of Clinical Pharmacy and Therapeutics , vol.45, no.2, 303-308.
Selcukbiricik, Fatih Et Al. "Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer," Journal of Clinical Pharmacy and Therapeutics , vol.45, no.2, 303-308, 2020
Selcukbiricik, Fatih Et Al. "Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer." Journal of Clinical Pharmacy and Therapeutics , vol.45, no.2, pp.303-308, 2020
Selcukbiricik, F. Et Al. (2020) . "Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer." Journal of Clinical Pharmacy and Therapeutics , vol.45, no.2, pp.303-308.
@article{article, author={Fatih Selcukbiricik Et Al. }, title={Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer}, journal={Journal of Clinical Pharmacy and Therapeutics}, year=2020, pages={303-308} }